team-Kristen-Sheppard

Kristen Sheppard Esq

Senior Vice President, Investor Relations and Corporate Communications

Kristen Sheppard joined Centessa in June 2022 as Senior Vice President, Investor Relations and Corporate Communications. Ms. Sheppard has more than 25 years of experience in building and leading successful investor relations, corporate communications and public affairs functions across the biotechnology, medical device and technology sectors.

Ms. Sheppard joined Centessa from Dicerna Pharmaceuticals, Inc. where she served as Senior Vice President, Investor Relations and Corporate Communications through its acquisition by Novo Nordisk. Prior to Dicerna, Ms. Sheppard was Senior Vice President, Investor Relations and Corporate Communications at Akebia Therapeutics, Inc. Ms. Sheppard was also Vice President, Investor Relations and Counsel at NxStage Medical, Inc. from 2008 through its acquisition by Fresenius Medical Care in 2019, serving most recently as the company’s Associate General Counsel. Prior to NxStage, Ms. Sheppard held senior leadership roles in investor relations for publicly traded and pre-IPO companies within the technology sector, and also served as senior government affairs and public policy counsel to various healthcare entities.

Ms. Sheppard holds a Juris Doctor from Suffolk University Law School and a Bachelor of Arts in political science from the University of New Hampshire. She is a member of the New Hampshire Bar Association.

Scroll to Top
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B